End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations

Core Viewpoint - Apogee Therapeutics Inc. (NASDAQ:APGE) is identified as one of the 13 stocks with significant upside potential, despite recent adjustments in price targets and sales forecasts by analysts [1][2]. Group 1: Analyst Adjustments - Jefferies has lowered its price target for Apogee Therapeutics from $98 to $95 while maintaining a Buy rating [1]. - The risk-adjusted peak sales forecast for Apogee's '279 combination therapy has been reduced from $1.8 billion to $1.6 billion due to anticipated limitations in high-risk patients [1]. - The share price of Apogee fell by 6% following the discontinuation of Amgen's OX40 collaboration, which has influenced analyst expectations [2]. Group 2: Market Context - The discontinuation of the OX40 collaboration and the deprioritization of amlitelimab by Sanofi are significant events impacting Apogee's market position [2]. - Despite these challenges, analysts do not expect Kaposi's Sarcoma to significantly affect the commercial potential of OX40 therapies, although a potential black box warning for high-risk populations is anticipated [2]. - Apogee Therapeutics focuses on developing treatments for atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications [3].